Personal Information
Organization / Workplace
Egypt Egypt
Occupation
Professor of Clinical Oncology, Cairo University
Website
www.oncologyclinic.org
Tags
metastatic colorectal cancer
chemotherapy
immunotherapy
prostate cancer
angiogenesis
crpc
bevacizumab
colorectal cancer
enzalutamide
gastric cancer
colon cancer
adjuvant
denosumab
breast cancer
abiraterone acetate
ramucirumab
rectal cancer
neoadjuvant
radiation therapy
cetuximab
bone metastases
parp inhibitors
guidelines
metastatic colon cancer
molecular subtypes
sidedness
regorafinib
cinv
metastatic prostate cancer
pd1
total neoadjuvant
anti-egfr therapy
docetaxel
cabazitaxel
targeted therapy
castrate resistant
avoid surgery in rectal cancer
androgen deprivation therapy
bone health
mtor inhibitors
everolimus
cancer
aflibercept.
anti-angiogenic therapy
panitumumab
metastatic
zoladronic acid
advanced
important
2023
brca mutation
metastatic disease
triple negative
ovarian cancer
long acting somatostatin receptor analogues
neuroendocrine tumors
olaparib
platinum sensitivity and resistance
cjemoresistant
chemosensitive
high grade serous
cancer ovary
tas 102
nonmetastatic
apaultamide
achievements
aims of treatment
strategy
basic principles
cancer management
treatment sequence
pathophysiology
sensitive
apalutamide
hspc
enhanced survival
treatment
1ry tumor location
short course
long course
concurrent therapy
disease stabilizaton
non crc
crc
msi h
vegf
egfr
left colon
right colon
adt
mhspc
ctla4
pd/l1
checkpoint inhibitors
subsequent treatment lines in mcrc
3rd line treatment
vomiting and chemotherapy
nausea and chemotherapy
tumor location
right versus left colon cancer
first line
advanced and metastatic
her2neu
androgen receptor and biosynthesis
biology
lhrh
rankl inhibitors
bone cancer
pd-l1
ctl4
ngs
mmr
anti-pd- 1 directed therapy.
msi
pazobanip
nivolumam
cabozantinibnib
tki
mtor
renal cell carcinoma
neoadjuvant therapy
pcr
adjuvant therapy
watch and wait database
near total neoadjuvant
pitfalls
solution and management
problems
liver limited disease of colorectal cancer origin
medical management
prostatectomy
updates asco gi 2017
molecular sutying
trastusumab
early tumor shrinkage
urology debates
updates in urology
mcrc
mdt
management
abiraterone
hormonal therapy
oligometasdtases
cancer minded
basic knowledge
bone physiology
giant cell tumor of bones
target therapy
molecular basis
genetic signature
sequencing
updates asco gi 2016
circumfrential resection margins
chemoradiation
targeted therapies
molecular background
skeletal related events sre
bisphosphonates
gastric
andti-egfr anti-vegf
liver metastases
skeletal related events
economic burden
updated informations - evidence based medicine
brain metastases.
rapid arc
brain
radiosurgery
rcc
neuroendocrine
sunitinib
tme
rectal
angiogensis
screening
anti-angiogenic.
anti-epidermal growth factor receptor
aflibercept
head and neck cancers
radiation therapy.
cancer breast
management of skeletal related events
cancer prostate
systemic treatment.
trastuzumab
her 2 neu
See more
Presentations
(86)Likes
(9)M rcc reempowering an old dogma
Mohamed Abdulla
•
7 years ago
MCO 2011 - Slide 4 - K. Fizazi - Castration-refractory prostate cancer
European School of Oncology
•
13 years ago
Clinical Applications of Next Generation Sequencing
Bell Symposium & MSP Seminar
•
10 years ago
Rectal cancer pacc 16
Mohamed Abdulla
•
8 years ago
Crpc the paradigm of sequence
Mohamed Abdulla
•
8 years ago
t 2006
Flavio Guzmán
•
14 years ago
Radiation therapy for early breast cancer bgicc 2015
Mohamed Abdulla
•
9 years ago
Cetuximab in scchn how far we go?
Mohamed Abdulla
•
9 years ago
Giant cell tumor of bone
orthoprince
•
10 years ago
Personal Information
Organization / Workplace
Egypt Egypt
Occupation
Professor of Clinical Oncology, Cairo University
Website
www.oncologyclinic.org
Tags
metastatic colorectal cancer
chemotherapy
immunotherapy
prostate cancer
angiogenesis
crpc
bevacizumab
colorectal cancer
enzalutamide
gastric cancer
colon cancer
adjuvant
denosumab
breast cancer
abiraterone acetate
ramucirumab
rectal cancer
neoadjuvant
radiation therapy
cetuximab
bone metastases
parp inhibitors
guidelines
metastatic colon cancer
molecular subtypes
sidedness
regorafinib
cinv
metastatic prostate cancer
pd1
total neoadjuvant
anti-egfr therapy
docetaxel
cabazitaxel
targeted therapy
castrate resistant
avoid surgery in rectal cancer
androgen deprivation therapy
bone health
mtor inhibitors
everolimus
cancer
aflibercept.
anti-angiogenic therapy
panitumumab
metastatic
zoladronic acid
advanced
important
2023
brca mutation
metastatic disease
triple negative
ovarian cancer
long acting somatostatin receptor analogues
neuroendocrine tumors
olaparib
platinum sensitivity and resistance
cjemoresistant
chemosensitive
high grade serous
cancer ovary
tas 102
nonmetastatic
apaultamide
achievements
aims of treatment
strategy
basic principles
cancer management
treatment sequence
pathophysiology
sensitive
apalutamide
hspc
enhanced survival
treatment
1ry tumor location
short course
long course
concurrent therapy
disease stabilizaton
non crc
crc
msi h
vegf
egfr
left colon
right colon
adt
mhspc
ctla4
pd/l1
checkpoint inhibitors
subsequent treatment lines in mcrc
3rd line treatment
vomiting and chemotherapy
nausea and chemotherapy
tumor location
right versus left colon cancer
first line
advanced and metastatic
her2neu
androgen receptor and biosynthesis
biology
lhrh
rankl inhibitors
bone cancer
pd-l1
ctl4
ngs
mmr
anti-pd- 1 directed therapy.
msi
pazobanip
nivolumam
cabozantinibnib
tki
mtor
renal cell carcinoma
neoadjuvant therapy
pcr
adjuvant therapy
watch and wait database
near total neoadjuvant
pitfalls
solution and management
problems
liver limited disease of colorectal cancer origin
medical management
prostatectomy
updates asco gi 2017
molecular sutying
trastusumab
early tumor shrinkage
urology debates
updates in urology
mcrc
mdt
management
abiraterone
hormonal therapy
oligometasdtases
cancer minded
basic knowledge
bone physiology
giant cell tumor of bones
target therapy
molecular basis
genetic signature
sequencing
updates asco gi 2016
circumfrential resection margins
chemoradiation
targeted therapies
molecular background
skeletal related events sre
bisphosphonates
gastric
andti-egfr anti-vegf
liver metastases
skeletal related events
economic burden
updated informations - evidence based medicine
brain metastases.
rapid arc
brain
radiosurgery
rcc
neuroendocrine
sunitinib
tme
rectal
angiogensis
screening
anti-angiogenic.
anti-epidermal growth factor receptor
aflibercept
head and neck cancers
radiation therapy.
cancer breast
management of skeletal related events
cancer prostate
systemic treatment.
trastuzumab
her 2 neu
See more